Department of Chest Medicine

Koo Foundation Sun Yat-Sen Cancer Center

Breast Cancer

Ovarian Cancer

Ovarian Epithelial Carcinoma

Cancer

Nasopharyngeal Cancer

Brain Cancer

Glioblastoma

Avelumab

Platinum

Capecitabine

Pembrolizumab

Temozolomide

Doxorubicin

Cyclophosphamide

Pfizer

Aston Sci.

National Cancer Institute (NCI)

Novelwise Pharmaceutical

OBI Pharma

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Koo Foundation Sun Yat-Sen Cancer Center | Department of Chest Medicine

Site insights

Work at this site?

Active trials

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

Trial sponsors